NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875. | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer | 05/08 | 09/10 | | |
| Completed | 2 | 41 | Europe | Oxaliplatin, Sorafenib | Grupo Espanol Multidisciplinario del Cancer Digestivo | Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment) | 10/11 | 12/11 | | |
| Completed | 2 | 54 | Europe | sorafenib tosylate, laboratory biomarker analysis | Cancer Trials Ireland | Esophageal Cancer, Gastric Cancer | 11/12 | | | |
NCT00917462: Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 35 | US | Sorafenib, administered orally, CT/MRI | Memorial Sloan Kettering Cancer Center, Bayer | Esophageal Cancer, Gastroesophageal Junction Cancer | 08/18 | 08/18 | | |
